| Literature DB >> 33955822 |
Emelie Stenman1, Karolina Palmér1, Stefan Rydén2, Charlotta Sävblom3, Jianguang Ji1, Jan Sundquist1,4,5,6.
Abstract
OBJECTIVE: To evaluate compliance to workflow and accuracy of tests in Sweden's first fast-track referral pathway for patients with nonspecific symptoms and suspected cancer (SCAN).Entities:
Keywords: Neoplasms; cancer; guideline adherence; nonspecific symptoms; test accuracy
Mesh:
Year: 2021 PMID: 33955822 PMCID: PMC8293951 DOI: 10.1080/02813432.2021.1913892
Source DB: PubMed Journal: Scand J Prim Health Care ISSN: 0281-3432 Impact factor: 2.581
Test packages in the DC workflow.
| Primary care package 1 | Primary care package 2 | DC-package |
|---|---|---|
Hemoglobin (Hb) Erythrocyte sedimentation rate (ESR) C-reactive protein (CRP) Glucose Uric acid Feces hemoglobin Electrocardiography (ECG) Peak expiratory flow (PEF) Oxygen saturation | Thyroid-stimulating hormone (TSH) Blood leukocytes Creatinine Potassium Alanine aminotransferase (ALAT) Gamma-glutamyltransferase (GT) Alkaline phosphatase (ALP) Amylase Calcium Albumin Homocysteine | Iron TIBC Sodium Cystatin Calcium ion Uric acid Bilirubin NT-pro-BNP HbA1c a-tTG IgA ANA, anti-DNA, anti-ENA, anti-cardiolipin Hepatitis A Blood screening (HIV, hepatitis B and hepatitis C) Borrelia Epstein Barr virus Cytomegalovirus PSA (men) |
ANA: antinuclear antibodies, a-tTG: anti-tissue transglutaminase, ENA: extractable nuclear antigens NT-pro-BNP: N-terminal pro-brain natriuretic peptide, PSA: prostate-specific antigen, TIBC: total iron-binding capacity.
Figure 1.The DC workflow. Contents of primary care packages 1 and 2 and the DC-package are shown in Table 1.
Patient characteristics and compliance to compulsory tests in primary care.
| All patients ( | Patients diagnosed with cancer ( | Patients diagnosed with other diseases, not cancer ( | Patients with no diagnosis ( | |
|---|---|---|---|---|
| Age, median (IQR) | 69 (59–76) | 71 (65–77) | 69 (59–76) | 66 (53–74) |
| Sex (male/female)a, % | 48/52 | 58/42 | 47/53 | 41/59 |
| Education (low/middle/high)a, % | 46/36/18 | 43/41/16 | 47/36/17 | 47/29/24 |
| Marital status (married or live together/single)a, % | 69/31 | 67/33 | 70/30 | 65/35 |
| Born in Sweden (yes/no)a, % | 95/5 | 94/6 | 94/6 | 97/3 |
| Primary care package 1 | ||||
| All 9 tests, number of patients | 30 (10%) | 2 (3%) | 23 (12%) | 5 (13%) |
| At least one test, number of patients | 282 (97%) | 61 (95%) | 182 (98%) | 39 (98%) |
| Number tests taken, median (IQR) | 5 (4–7) | 4 (3–5) | 5 (4–8) | 6 (4–7) |
| Primary care package 2 | ||||
| All 11 tests, number of patients | 89 (31%) | 13 (20%) | 61 (33%) | 15 (38%) |
| At least one test, number of patients | 282 (97%) | 60 (94%) | 183 (98%) | 39 (98%) |
| Number tests taken, median (IQR) | 9 (7–11) | 8 (6–10) | 9 (7–11) | 10 (8–11) |
| Pulmonary X-ray, number of patients | 191 (66%) | 41 (64%) | 125 (67%) | 25 (63%) |
| Ultrasound, number of patients | 165 (57%) | 32 (50%) | 109 (59%) | 24 (60%) |
| Tests before referral to the DCb | ||||
| Number tests takenc, median (IQR) | 15 (12–19) | 14 (11–16) | 15 (12–19) | 17 (14–20) |
| Number abnormal, median (IQR) | 3 (2–6) | 5 (3–6) | 3 (2–6) | 1 (0–3) |
| Number normal, median (IQR) | 11 (8–15) | 8 (6–11) | 12 (9–15) | 15 (10–17) |
a48 patients (17%) had missing information on any of sex, education, marital status or born in Sweden (23%, 14% and 18% in patients with cancer, other diseases and no diagnosis, respectively).
bPackage 1 (9 possible tests), package 2 (11 possible tests) and pulmonary X-ray + ultrasound (in total 22 possible tests and examinations).
cFive patients (1.7%) did not take any test at all in primary health care (3, 2 and 0 in patients with cancer, other diseases and no diagnosis, respectively).
Compliance to and test accuracy of the DC package.
| Test | Taken | Abnormal | Normal | Sens | Spec | PPV | NPV | LRa | Negative post-test probabilityb | Positive post-test probabilityc |
|---|---|---|---|---|---|---|---|---|---|---|
| DC-package: | ||||||||||
| Iron | 165 (57) | 51 (31) | 114 (69) | 48 | 73 | 28 | 87 | 1.8 | 16.7 (10.6–23.6) | 33.3 (21.8–45.6) |
| IBC | 163 (56) | 16 (10) | 147 (90) | 14 | 91 | 25 | 83 | 1.5 | 21.0 (15.9–26.5) | 30.8 (11.8–55.5) |
| Sodium | 192 (66) | 13(7) | 179 (93) | 16 | 96 | 46 | 82 | 3.5 | 19.9 (15.1–25.2) | 49.7 (25.4–73.7) |
| Cystatin | 121 (42) | 30 (25) | 91 (75) | 41 | 79 | 30 | 86 | 1.9 | 17.4 (11.3–24.2) | 35.2 (20.7–51.0) |
| Calcium ion | 146 (50) | 11 (8) | 135 (93) | 15 | 94 | 36 | 83 | 2.5 | 20.3 (15.2–25.7) | 41.8 (16.5–69.0) |
| Uric acid | 121 (42) | 16 (13) | 105 (87) | 20 | 88 | 25 | 85 | 1.7 | 20.3 (14.6–26.3) | 32.5 (12.7–55.8) |
| Bilirubin | 169 (58) | 8 (5) | 161 (95) | 17 | 99 | 75 | 82 | 11.5 | 19.1 (14.5–24.3) | 75.4 (42.7–94.6) |
| NT-pro-BNP | 123 (42) | 23 (19) | 100 (81) | 26 | 83 | 26 | 83 | 1.5 | 20.0 (14.3–26.3) | 30.4 (14.0–49.0) |
| HbA1c | 135 (47) | 25 (19) | 110 (82) | 25 | 83 | 28 | 81 | 1.5 | 20.3 (14.8–26.3) | 29.6 (15.1–47.5) |
| a-tTG IgA | 121 (42) | 3 (3) | 118 (98) | 0 | 97 | 0 | 84 | 0.0 | 22.3 (17.5–27.4) | 10.0 (0.0–62.1) |
| ANA, anti-DNA, anti-ENA, anti-cardiolipin | 118 (41) | 22 (19) | 96 (81) | 16 | 81 | 14 | 83 | 0.8 | 22.5 (16.3–29.0) | 19.2 (6.1–38.9) |
| Hepatitis A | 106 (37) | 1 (0.9) | 105 (99) | 0 | 99 | 0 | 83 | 0.0 | 21.9 (17.3–27.1) | 21.1 (0.1–88.6) |
| Blood screening | 115 (40) | 1 (1) | 114 (99) | 0 | 99 | 0 | 84 | 0.0 | 22.0 (17.2–27.1) | 23.3 (0.0–89.8) |
| Borrelia | 124 (43) | 9 (7) | 115 (93) | 21 | 95 | 44 | 87 | 4.4 | 18.9 (13.4–24.5) | 55.0 (25.6–80.8) |
| Epstein Barr virus | 110 (38) | 2 (2) | 108 (98) | 0 | 98 | 0 | 84 | 0.0 | 22.1 (17.3–27.3) | 13.4 (0.0–73.3) |
| Cytomegalovirus | 110 (38) | 3 (3) | 107 (97) | 12 | 99 | 67 | 86 | 10.9 | 19.9 (14.7–25.2) | 73.4 (26.3–97.1) |
| P-PSA (only men) | 91 (65) | 25 (28) | 66 (73) | 28 | 73 | 28 | 73 | 1.0 | 21.9 (15.5–28.8) | 27.1 (13.1–44.4) |
aLR: likelihood ratio (estimation of how much an abnormal test result increases the probability of cancer).
bNegative post-test probability (probability of cancer after a normal test result).
cPositive post-test probability (probability of cancer after an abnormal test result).
Figure 2.Number of abnormal/pathological test results of compulsory tests (packages 1 + 2 and pulmonary X-ray and ultrasound) in the primary health care. * Number of patients with cancer that had all tests normal.